Cord Blood Stem Cell-derived DCs Generate Potent Antigen-Specific Immune Responses and Anti-tumor Effects.
Clin Sci (Lond). 2012 Jan 23;
Authors: Chang MC, Lee CN, Chen YL, Chiang YC, Sun WZ, Hu YH, Chen CA, Cheng WF
Abstract
This study aims to evaluate if cord blood stem cells (CBSCs) can be new source of dendritic cells (DCs) which can generate more potent antigen-specific immune responses and anti-tumor effects. The CBSCs and peripheral blood mononuclear cells (PBMCs) were collected, cultured and differentiated into DCs. Surface markers, secreting cytokines, antigen presentation activity, antigen-specific cell-mediated immunity and cytotoxic killing effects induced by these two origins of DCs were evaluated and compared. The CBSCs expanded for ~17-fold by ex vivo culture. The expressions of surface markers in CBSC-derived DCs were higher than those in PBMC-derived DCs treated with LPS. The CBSC-derived DCs mainly secreted IL-6, IL-10, and TNF-a, while PBMC-derived DCs mainly secreted IL-5 and IFN-γ. The CBSC-derived DCs had better antigen presentation abilities when stimulated with LPS or TNF-a, induced higher numbers of IFN-g-secreting, antigen-specific CD8+ T lymphocytes by ELLIspot assay, and stimulated stronger antigen-specific CTL activities (p<0.01, one-way ANOVA). The CBSC-derived DCs showed quicker and stronger ERK and Akt phosphorylation, and weaker p38 phosphorylation than PBMC-derived DCs when stimulated with LPS. The CBSC-derived DCs have abilities of inducing stronger antigen-specific immunity and more potent anti-tumor effects. The CBSCs can be a good source of DCs in the strategy of DC-based cancer vaccine and immunotherapy.
PMID: 22264240 [PubMed - as supplied by publisher]